Pantoprazol Aptapharma (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Aptapharma, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Pantoprazol Aptapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Aptapharma belongs to the proton pump inhibitor class and is indicated for conditions driven by excess gastric acid secretion. - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with gastrin‑producing tumours.

Pantoprazol Aptapharma may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Acute interstitial nephritis: kidney inflammation with reduced urine output. - Severe hypersensitivity: rash, itching, swelling or anaphylaxis. - Osteoporosis‑related fractures: increased risk of hip or vertebral fractures with long‑term use. - Vitamin B12 deficiency: low levels causing fatigue and neuropathy. - Liver enzyme elevation: raised ALT/AST indicating hepatic stress.

When prescribing Pantoprazol Aptapharma, clinicians should consider several safety aspects. - Assess renal function: adjust dose in severe renal impairment. - Review concomitant medications: avoid unnecessary combinations that increase infection risk. - Limit duration: use the lowest effective dose for the shortest period needed. - Monitor bone health: consider calcium and vitamin D supplementation for long‑term users. - Evaluate for H. pylori infection: treat infection before initiating therapy when appropriate. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazol Aptapharma can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Antifungal azoles (ketoconazole, itraconazole): reduced absorption due to increased gastric pH. - HIV protease inhibitors (lopinavir/ritonavir): decreased bioavailability. - Clopidogrel: diminished antiplatelet effect increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR values. - Methotrexate: reduced renal clearance may raise serum levels. - Digoxin: modest increase in serum concentration. - Oral contraceptives: possible decrease in efficacy.